18 Jul Axent Biosciences
Hunter Johnson, Ph.D., CEO
Oct. 7 | 5:15pm | FLW Ballroom F
Berkeley, CA
(Private)
Axent Biosciences is a pre-clinical stage company that aims to revolutionize the field of cell therapy by leveraging a simple, safe and scalable cell cultivation technology to produce best-in-class cells with industry-leading yields. Axent’s platform relies on a novel synthetic 3D matrix that supports robust cell growth and differentiation while enabling commercial-scale production. This system overcomes key challenges in stem cell manufacturing, including genomic instability, low yields, and poor reproducibility, by providing a xeno-free, shear-protected environment compatible with multiple bioreactor configurations. Cells produced in Axent’s platform exhibit high viability, genomic stability over 10 passages, and superior potency. This technology is compatible with standard differentiation media components and delivers significantly higher cell yields (5-10M/mL) and fold changes (>100 fold) than traditional methods. This breakthrough enables the first-ever commercial-scale production of cell therapies for high-demand indications including Type 1 Diabetes, Liver Disease and Heart Failure.
